Zimmers #AACR23 Concludes - cachexia is generally untreated; cancer drives it through specific, targetable therapie… https://t.co/wH74aDIT6R
11:02am April 16th 2023 via Twitter Web App
Zimmers #AACR23 Blocking muscle wasting impede pancreatic tumor growth. Preprint in Nature https://t.co/jdAsrNsXRI
10:59am April 16th 2023 via Twitter Web App
Zimmers #AACR23 IL-6 mediates feed forward inflammaiton, cachexia, and tumor progression in the macroenvironment. A… https://t.co/EkD5HOehLg
10:56am April 16th 2023 via Twitter Web App
Zimmers #AACR23 On to GDF-15, opportunity and in Ph I clinical trials for cachexia. https://t.co/FFltkXONnE
10:55am April 16th 2023 via Twitter Web App
Zimmers #AACR23 Shows prolonged survival in mice. Cachexia is sexually dimorphic; only males respond to activin inh… https://t.co/g81JrA0YOv
10:53am April 16th 2023 via Twitter Web App
Zimmers #AACR23 Myostatin inhibition was protective in mouse models of lung cancer, and colon carcinoma. But failed… https://t.co/8neqdtcYho
10:51am April 16th 2023 via Twitter Web App
Zimmers #AACR23 Looking at mediators - metabolic, proteomic. CDF-8 deficiency causes muscle hypertropy. Myostatin -… https://t.co/fCSA2otdh3
10:49am April 16th 2023 via Twitter Web App
Zimmers #AACR23 ASCO guidelines for managing cachexia. https://t.co/xcTTttSvi0
10:48am April 16th 2023 via Twitter Web App
Zimmers #AACR23 <5% weight loss in 6 mos. Often precedes diagnosis of life-threatening cancer. Underdiagnosed as a… https://t.co/wk3h3eOD
10:47am April 16th 2023 via Twitter Web App
Zimmers #AACR23 Weakness, 'I could see my bones against my skin, a living X-ray" - From Kalanthi's excellent "When… https://t.co/nV8qRY8k9w
10:46am April 16th 2023 via Twitter Web App
Teresa Zimmers (OHSU Knight Cancer Inst OR) #AACR23 Cancer cachexia: Out of intense complexities, intense simplicit… https://t.co/t9xEF3FY4x
10:44am April 16th 2023 via Twitter Web App
DeNardo #AACR23 TMEs are heterogenous across cancers, organs and patients. Take advantage of TME vulnerabilities, and TME addiction.
10:42am April 16th 2023 via Twitter Web App
DeNardo #AACR23 Look at TME's as an opportunity for tehrapy. 'Exploit the TME to re-ignite tumor immunity'. Combine… https://t.co/U4KUZI4E31
10:39am April 16th 2023 via Twitter Web App
DeNardo #AACR23 Points out the challenge of diverse TMEs - myeloid rich, immune poor, desmoplastic, T-cell inflamed… https://t.co/JnS3UuIGmi
10:37am April 16th 2023 via Twitter Web App
DeNardo #AACR23 Cancer is a systemic disease, and tumor immunity is systemic as well. Modeling organ-spec tumor imm… https://t.co/QGXHdGA5jH
10:35am April 16th 2023 via Twitter Web App
DeNardo #AACR23 A systemic response - organ tissue, and the diverse TME's. Systemic: lymphopenia, expansion of imma… https://t.co/D6cEhbKivW
10:31am April 16th 2023 via Twitter Web App
DeNardo #AACR23 PDAC is the flagship - lacking I-O response. Glioblastoma, gastric cancers. Some have high t-cell n… https://t.co/f0CnkOVWZa
10:30am April 16th 2023 via Twitter Web App
DeNardo #AACR23 There is a diversity of immunotherapy approaches - CAR-T, vaccines, bispecific Abs, activating immu… https://t.co/fhXsTifWyS
10:27am April 16th 2023 via Twitter Web App
David DeNardo (Washington Univ MO) #AACR23 Learning tumor immunology from immunotherapy success and failures. >20%… https://t.co/KVsg6vqw
10:26am April 16th 2023 via Twitter Web App
Schrag #AACR23 Avoid perils - need RCTs and rigor in study design. Need nimble, pragmatic design. Be aware of stres… https://t.co/TWjy6BolAi
10:23am April 16th 2023 via Twitter Web App
Schrag #AACR23 Concludes: Opportunity to come together. Access to samples to developers. Encourage participation. N… https://t.co/aSNMDiX1Lj
10:22am April 16th 2023 via Twitter Web App
Schrag #AACR23 ARPA-H may want to take this up. @theNCI is taking up the Vanguard Trial - 24K participants, eval 2… https://t.co/YfVtsAABzI
10:20am April 16th 2023 via Twitter Web App
Schrag #AACR23 need to invest in a 'large volume of "gold std" labeled patient samples. Say 5K that oversample earl… https://t.co/floYzMKOLu
10:19am April 16th 2023 via Twitter Web App
Schrag #AACR23 US approval for MCED is mulit-step -analytical validity, clinical validity and utility, then balance… https://t.co/CJEQmZK1EG
10:17am April 16th 2023 via Twitter Web App
Schrag #AACR23 Lead time, and length time bias - screening test easy to overdiagnose "an extreme form of length bia… https://t.co/YaAM9w5deE
10:16am April 16th 2023 via Twitter Web App
Schrag #AACR23 1.4% cancer signal, spec 99.1%, PPV 38%. PPV improved to 43.1%. Implications - est Sensitivity is '… https://t.co/vp71y1RcbI
10:15am April 16th 2023 via Twitter Web App
Schrag #AACR23 35 diagnosed with 36 cancers. 29/24 were correct Tumor Tissue of Origin. Goes into examples. 74yo wo… https://t.co/aAJHg7EEGx
10:10am April 16th 2023 via Twitter Web App
Schrag #AACR23 MCED in Pathfinder (using Grail's methylated cfDNA assay). Goals: dx evaluations by a 'signal recei… https://t.co/KdDp54Dpbt
10:09am April 16th 2023 via Twitter Web App
Schrag #AACR23 Cancer is #2 cause of cancer deaths. But cancer screening is for only four cancers - cervical, breas… https://t.co/tS6xoI7x0g
10:07am April 16th 2023 via Twitter Web App
Deborah Schrag (Memorial Sloan Kettering Cancer Center NY) #AACR23 "Translating knowledge from panels to practice t… https://t.co/6sApczDS7H
10:05am April 16th 2023 via Twitter Web App
Deborah Schrag (Memorial Sloan Kettering Cancer Center NY) "Translating knowledge from panels to practice to popula… https://t.co/cXIZjwz5Hf
10:04am April 16th 2023 via Twitter Web App
Vonderheide #AACR23 - Four tips for a successful AACR: 1) attend each morning's plenary, there's something for ever… https://t.co/Fp8uOXtRoO
10:02am April 16th 2023 via Twitter Web App
Bob Vonderheide (U Penn PA) #AACR23 Program Meeting Chair. 23K attendees; 600 oral presentations; record number of… https://t.co/MZIB3xdpEr
10:00am April 16th 2023 via Twitter Web App
Bertagnoli #AACR23 Plan details in the Cancer Moonshot this afternoon, another Director's address (Mon).
9:55am April 16th 2023 via Twitter Web App
Bertagnoli #AACR23 Announces a new National Cancer Plan https://t.co/nuWNCzL4ya to see the 'full range of what is n… https://t.co/aXXdvcQy51
9:52am April 16th 2023 via Twitter Web App
Bertagnoli #AACR23 Many remember how hopeless metastatic melanoma used to be. "We all need to move forward with pur… https://t.co/bWTxSLxREy
9:50am April 16th 2023 via Twitter Web App
Bertagnoli #AACR23 Shows this survival data for melanoma, a bright spot. https://t.co/AZPMeyMtlU
9:48am April 16th 2023 via Twitter for iPhone
Bertagnoli #AACR23 Credits Dr. Richard E Wilson early in her surgical oncology career, who he himself was a cancer… https://t.co/8AQNK0QV7g
9:47am April 16th 2023 via Twitter Web App
New director of @theNCI Dr Monica Bertagnoli giving the #AACR23 plenary talk, Ending Cancer as we Know it: Everyone… https://t.co/BjJvtCtggi
9:45am April 16th 2023 via Twitter for iPhone
Recognition of Nobel Prize winner Dr Bertolucci, and 22 additional new fellows including Stephen Chanock of @theNCI… https://t.co/75tOSIDuZY
9:17am April 16th 2023 via Twitter for iPhone
Award for the #AACR23 Team Science award goes to the African_Caribbean Cancer Consortium (AC3) “addressing the canc… https://t.co/nLHuxOrvmL
8:50am April 16th 2023 via Twitter for iPhone
Phyllis Pettit Nassi at #AACR23 from @huntsmancancer recognized for her efforts ilas a patient advocate for America… https://t.co/Kkc9NZATHi
8:43am April 16th 2023 via Twitter for iPhone
Carl June at #AACR23 opening session receiving a lifetime achievement award. https://t.co/xa2duV553Q
8:35am April 16th 2023 via Twitter for iPhone
RT @OncoAlert: A Great Day2⃣ of #AACR23
8:33am April 16th 2023 via Twitter Web App
Carreno #AACR23 DC vaccination elicits T-cell immunity against mKRAS neoantigen. (Will stop tweeting, notified 'do not post'.)
5:52pm April 15th 2023 via Twitter Web App
Carreno #AACR23 Synthetic peptides act as beacons to point to real immunopeptides. Shown they are 'mirror images' o… https://t.co/apmhkULOXr
5:50pm April 15th 2023 via Twitter Web App
Carreno #AACR23 mKRAS neoantigen and TCR discovery platform. Bioinf predict affinity, measure affinity, proteomics… https://t.co/PeQvqs3DZk
5:48pm April 15th 2023 via Twitter Web App
Carreno #AACR23 Proof of concept: Adoptive transfer of TILs. Loss of class I was a mechanism of immune evasion 2016… https://t.co/ouNWs7O2Jy
5:46pm April 15th 2023 via Twitter Web App
Carreno #AACR23 Mutated KRAS elicits T-cell immunity. VAccines, and adjuvants, specific to G12V, G12D. 1995 Lancet https://t.co/3kBoh7BU7O
5:45pm April 15th 2023 via Twitter Web App
Beatriz Carreno (Univ Pennsylvania PA) #AACR23 KRAS is Personal: Just ask the immune system
5:44pm April 15th 2023 via Twitter Web App
